Add‐on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: A prospective observational study
Epilepsia · 2024-03 · 65 (3) · 630-640
DOI: 10.1111/epi.17874 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Epilepsia, online erschienen am 10.01.2024. Verfasst von Yulia Novitskaya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Freiburg Epilepsy Center, Medical Center, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Epilepsies, Partial, Drug Resistant Epilepsy, Drug-Related Side Effects and Adverse Reactions, Carbamates. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Cenobamate, a novel antiseizure medication with a dual mechanism of action, has been shown in pivotal trials to significantly improve seizure control in treatment‐resistant focal epilepsy. We aimed to evaluate whether these promising results could be confirmed in a real‐world setting with a follow‐up period of up to 12 months.
Methods
Patients from a tertiary epilepsy center who received cenobamate add‐on between June 2021 and October 2023 were followed up prospectively at 3, 6, and 12 months after treatment initiation for assessment of seizure outcomes and treatment‐related adverse events.
Results
The clinical cohort included 112 adult patients with 30% nonlesional cases and a wide spectrum of epileptogenic lesions underlying refractory focal epilepsy. We observed a significant reduction in monthly seizure frequency of all seizure types already after 3 months of treatment at a median cenobamate dose of 100 mg/day. Forty‐six percent of patients were responders with a ≥50% seizure reduction, 26% had a ≥75% seizure reduction, and 9% became seizure‐free. Among the 74 patients with available follow‐up of 12 months, the responder rates reached 55%, 35%, and 19% for ≥50%, ≥75%, and 100% seizure reduction, respectively. After 3 months of treatment, 38% of patients reported adverse effects, mainly (84%) mild to moderate in intensity. Adjustment of comedication allowed successful management of adverse effects in 32% of patients. At a group level, there was no correlation between the cenobamate daily dose and the incidence of adverse events. Significance We found a clinically relevant response to cenobamate already at a low daily dose of 100 mg also in a patient cohort with a higher degree of drug resistance than in pivotal trials. Our prospectively collected data provide real‐world evidence for high efficacy and good tolerability of the drug, although no standardized treatment protocol or comparison with a control group was applied.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Freiburg Epilepsy Center, Medical Center, University of Freiburg, Freiburg, Germany.
ORCID-Profile: Yulia Novitskaya, Elisa Schütz, Birgitta Metternich, Andreas Schulze-Bonhage, Martin Hirsch
Zitieren
APA
Novitskaya, Y., Schütz, E., Metternich, B., Schulze-Bonhage, A., & Hirsch, M. (2024). Add‐on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: A prospective observational study. Epilepsia, 65(3), 630-640. https://doi.org/10.1111/epi.17874
Vancouver
Novitskaya Y, Schütz E, Metternich B, Schulze-Bonhage A, Hirsch M. Add‐on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: A prospective observational study. Epilepsia. 2024;65(3):630-640. doi:10.1111/epi.17874
BibTeX
@article{Novitskaya2024,
author = {Novitskaya, Yulia and Schütz, Elisa and Metternich, Birgitta and Schulze-Bonhage, Andreas and Hirsch, Martin},
title = {Add‐on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: A prospective observational study},
journal = {Epilepsia},
year = {2024},
volume = {65},
number = {3},
pages = {630--640},
doi = {10.1111/epi.17874}
}
EUVIMED